共 50 条
Extended-Duration Therapy in Advanced Non-Small-Cell Lung Cancer: Promise and Pitfalls
被引:1
|作者:
Levy, Benjamin
[1
]
Drilon, Alexander
[1
]
Siu, KarLeung
[1
]
Grossbard, Michael
[1
]
机构:
[1] Beth Israel Hosp, New York, NY 10003 USA
关键词:
Carboplatin;
Cisplatin;
Doxorubicin;
Gemcitabine;
Methotrexate;
Navelbine;
Lomustine;
Paclitaxel;
PHASE-III TRIAL;
CISPLATIN PLUS GEMCITABINE;
RANDOMIZED-TRIAL;
1ST-LINE THERAPY;
SUPPORTIVE CARE;
CHEMOTHERAPY;
CARBOPLATIN;
PACLITAXEL;
GEFITINIB;
BEVACIZUMAB;
D O I:
10.3816/CLC.2010.n.050
中图分类号:
R73 [肿瘤学];
学科分类号:
100214 ;
摘要:
For many years, the cornerstone of treatment for non small-cell lung cancer (NSCLC) has been third-generation platinum-based chemotherapy. Unfortunately, clinical outcomes with the use of this approach have remained poor, with median survival times of only 8-13 months. In an attempt to improve survival, several therapeutic strategies have recently been investigated, including extended-duration chemotherapy. Although historically maintenance chemotherapy in NSCLC has resulted in less-than-optimal outcomes and there has been a recent surge in interest with this treatment modality. This has been in part because of the strategy of the early delivery of a non cross-resistant agent after platinum chemotherapy, now termed switch maintenance therapy. Results from several recent phase III trials using this strategy are shifting the treatment paradigm of patients with advanced-stage NSCLC. Despite more favorable outcomes demonstrated with this strategy, study designs and reported results have not been without critique. Here, we review all published extended-duration chemotherapy strategies in NSCLC and seek to clarify outstanding issues as they relate to more recent approaches using this strategy.
引用
收藏
页码:383 / 390
页数:8
相关论文